<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204640">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000332</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-3-0009-1</org_study_id>
    <secondary_id>Y01-3-0009-1</secondary_id>
    <nct_id>NCT00000332</nct_id>
  </id_info>
  <brief_title>High Dose Nimodipine Treatment Adjunct - 1</brief_title>
  <official_title>High Dose Nimodipine Pharmacotherapy Adjunct</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington D.C. Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if nimodipine is more effective than placebo in
      reducing stimulated craving for cocaine in cocaine dependent individuals denied access to
      cocaine in inpatient unit.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stimulated and non-stimulated craving</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Stimulated and non-stimulated withdrawal</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety, depression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate</measure>
  </primary_outcome>
  <enrollment>0</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimodipine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Please contact site for information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Deutsch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington D.C. Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington DC VA</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2002</verification_date>
  <lastchanged_date>June 2, 2015</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nimodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
